IP Library Granted Patent US 11,236,121
Granted Patent B2
US 11,236,121 · App. 16/326,977 · Granted Feb 1, 2022

Crystalline 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid

Inventors: Paul Steven Watson (Carrboro, NC); Bret Berner (Half Moon Bay, CA); John Gregory Reid (Wellington, FL); Jian Wang (Branchburg, NJ); James J. Doherty (Bedford, MA); Stephen Jay Kanes (Swarthmore, PA)
Assignee: Sage Therapeutics, Inc.
C07J43/003A61P25/00A61P25/08A61P25/18A61P25/22A61P25/24A61P37/00C07D231/14C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,236,121
App. No.
16/326,977
Filed
Feb 21, 2019
Granted
Feb 1, 2022
Kind
B2
Art Unit
1628
USPC
514/176
Abstract

This invention relates to a 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and crystalline solid forms and compositions thereof. Also disclosed herein are methods of making crystalline solid forms of the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) and methods of using the 19-nor C3,3-disubstituted C21-pyrazolyl steroid of Formula (I) or crystalline solid forms, pharmaceutically acceptable salts, and pharmaceutically acceptable compositions thereof.

Claims (8)

1. A crystalline solid form of Compound 1:

having an XRPD pattern comprising peaks between and including 9.7 to 10.1 degrees in 2θ, between and including 11.6 to 12.0 degrees in 2θ, between and including 13.2 to 13.6 degrees in 2θ, between and including 14.2 to 14.6 degrees in 2θ, between and including 14.6 to 15.0 degrees in 2θ, between and including 16.8 to 17.2 degrees in 2θ, between and including 20.5 to 20.9 degrees in 2θ, between and including 21.3 to 21.7 degrees in 2θ, between and including 21.4 to 21.8 degrees in 2θ, and between and including 22.4 to 22.8 degrees in 2θ.

2. The crystalline solid form of claim 1 , wherein the peak between and including 9.7 to 10.1 is 9.9 degrees in 2θ, the peak between and including 11.6 to 12.0 is 11.8 degrees in 2θ, the peak between and including 13.2 to 13.6 is 13.4 degrees in 2θ, the peak between and including 14.2 to 14.6 is 14.4 degrees in 2θ, the peak between and including 14.6 to 15.0 degrees is 14.8 in 20, the peak between and including 16.8 to 17.2 is 17.0 degrees in 2θ, the peak between and including 20.5 to 20.9 is 20.7 degrees in 2θ, the peak between and including 21.3 to 21.7 is 21.5 degrees in 2θ, the peak between and including 21.4 to 21.8 is 21.6 degrees in 2θ, and the peak between and including 22.4 to 22.8 is 22.6 degrees in 2θ.

3. A crystalline solid form of Compound 1:

having an XRPD pattern comprising peaks between and including 9.7 to 10.1 degrees in 2θ, between and including 14.6 to 15.0 degrees in 2θ, between and including 16.8 to 17.2 degrees in 2θ, between and including 20.5 to 20.9 degrees in 2θ, between and including 21.3 to 21.7 degrees in 2θ.

4. The crystalline solid form of claim 3 , wherein the peak between and including 9.7 to 10.1 is 9.9 degrees in 2θ, the peak between and including 14.6 to 15.0 is 14.8 degrees in 2θ, the peak between and including 16.8 to 17.2 is 17.0 degrees in 2θ, the peak between and including 20.5 to 20.9 is 20.7 degrees in 2θ, and the peak between and including 21.3 to 21.7 is 21.5 degrees in 2θ.

5. The A crystalline solid form of Compound 1:

having an XRPD pattern comprising peaks at 9.9 degrees in 2θ, 14.8 degrees in 2θ, 17.0 degrees in 2θ, 20.7 degrees in 2θ, and 21.5 degrees in 2θ.

Assignments (1)
CHANGE OF NAME Recorded May 13, 2026
From: SAGE THERAPEUTICS, INC.
To: SAGE THERAPEUTICS, LLC
Reel/Frame 075610/0448 →
Continuity (2)
Provisional Application 62378582 · Aug 23, 2016
Related Publication 20190177359A1 · Jun 13, 2019
Cited By (9)
US 12,201,640 US 12,252,509 US 12,264,177 US 12,358,942 US 12,410,210 US 12,473,327 US 12,534,495 US 12,655,175 US 12,673,970